Parkinson's Disease Therapeutics in Major Developed Markets to 2021: PD Is the Second Most Common Neurodegenerative Disease Worldwide

The global Parkinson's Disease (PD) prevalence was estimated at 16.1 million in 2011, and after Alzheimer's disease it is the second most common neurodegenerative disease worldwide.

Parkinson's Disease (PD) is a progressive disease and, although not fatal, it can develop severe symptoms and complications that significantly impact upon the patient's quality of life. Symptoms for each stage can be categorized into early, moderate and advanced stages. Major motor symptoms of Parkinson's Disease (PD) include tremors and difficulty walking. Parkinson's Disease (PD) also gives rise to non-motor symptoms, such as dementia, depression, hallucinations and loss of taste and smell.

There are several different drug classes available to relieve Parkinson's Disease (PD) symptoms. The aim is for treatments to increase dopamine levels, which is substantially diminished in brains affected by Parkinson's Disease (PD). The most common therapies include levodopa, dopamine agonists and Monoamine Oxidase-B (MAO-B) inhibitors, with the choice of therapies dependent on patient symptoms and lifestyle. As the disease develops, the medication will need to be taken more strictly, due to the effect of drugs wearing off (known as off- time), which causes symptoms to return before the next dose.

With the current marketed drugs focusing primarily on symptomatic relief, Parkinson's Disease (PD) remains incurable, with a huge unmet need for disease-modifying therapies. However, due to the lack of clearly established clinical trial methodologies, replication of the benefits demonstrated by neuroprotective agents in the laboratory to human trials has proved challenging. More importantly, due to an incomplete understanding of the underlying mechanisms that cause the disease, a viable therapeutic target to halt or slow disease progression is currently not in scope, which limits the effectiveness of current product development programs.

Key Topics Covered:

1 Tables & Figures

2 Introduction

2.1 Disease Introduction

2.2 Symptoms

2.3 Etiology

2.4 Pathophysiology

2.5 Epidemiology

2.6 Disease Stages

2.7 Co-morbidities and Complications

2.8 Diagnosis

2.9 Assessment of Disease Severity

2.10 Treatment

2.11 Treatment Algorithm

3 Marketed Products

3.1 Overview

3.1.1 Dopamine Replacement Therapies

3.1.2 MAO-B Inhibitors

3.1.3 Dopamine Agonists

3.1.4 COMT Inhibitors

3.1.5 Other Drugs Targeting Non-motor Symptoms of PD

3.2 Comparative Efficacy and Safety

4 Pipeline for Parkinson's Disease

4.1 Overview

4.2 Pipeline Distribution by Mechanism of Action/Molecular Target

4.3 Clinical Trials

4.3.1 Failure Rate

4.3.2 Clinical Trial Duration

4.3.3 Clinical Trial Size

4.3.4 Comparison of Average Trial Metrics by Phase and Mechanism of Action

4.4 Promising Pipeline Molecules

4.4.1 Opicapone - Bial

4.4.2 Nuplazid (pimavanserin) - Acadia Pharmaceuticals

4.4.3 Nurelin (Amantadine Hydrochloride Extended-Release) - Adamas Pharmaceuticals

4.4.4 Tozadenant - Biotie Therapies

4.4.5 APL-130277 (apomorphine hydrochloride) - Cynapsus Therapeutics

4.4.6 P2B001 (pramipexole dihydrochloride + rasagiline mesylate) - Pharma Two B

4.4.7 DM-1992 (levodopa + carbidopa extended release) - Depomed

4.4.8 CVT-301 (levodopa) - Acorda Therapeutics

4.4.9 Dipraglurant Immediate-Release- Addex Therapeutics

4.4.10 Accordion Pill (levodopa and carbidopa) - Intec Pharma

4.4.11 ND-0612L (levodopa and carbidopa) - NeuroDerm

4.5 Heatmaps of Safety and Efficacy for Parkinson's Disease Pipeline and Marketed Products

4.6 Pipeline Product Heat Map and Product Competitiveness Framework

5 Market Forecast to 2021

5.1 Geographical Markets

5.2 Drivers and Barriers

6 Strategic Consolidations

6.1 Major Co-Development Deals

6.1.1 TechnoPhage Enters into Co-Development Agreement with University of Macau

6.1.2 Dainippon Sumitomo Pharma Enters into Research Agreement with CiRA and Hitachi

6.1.3 MJFF Enters into Agreement with Prothena

6.1.4 Ubiquigent Enters into Co-Development Agreement with UbiQ

6.1.5 23andMe Partners with Genentech

6.2 Major Licensing Deals

6.2.1 Cephalon Enters Into Licensing Agreement With Mesoblast For Regenerative Medicine

6.2.2 Dexcel Pharma Enters into Licensing Agreement with Ramot at Tel Aviv University

6.2.3 Neuropore Therapies Enters into Licensing Agreement with UCB

6.2.4 Catalent Pharma Solutions Enters into Licensing Agreement with Sellas Life Sciences

6.2.5 MedGenesis Therapeutix Enters into Licensing Agreement with Pfizer

7 Appendix

7.1 All Pipeline Drugs by Stage of Development

7.2 Market Forecasts to 2021

7.3 References

7.4 Abbreviations

7.5 Research Methodology

7.6 Secondary Research

7.7 Marketed Product Profiles

7.8 Late-Stage Pipeline Candidates

7.9 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products

7.10 Product Competitiveness Framework

7.11 Pipeline Analysis

7.12 Deals Data Analysis

7.13 Expert Panel Validation

7.14 Contact Us

7.15 Disclaimer

Companies Mentioned

- 23andMe

- Catalent Pharma Solutions

- Cephalon

- Dainippon Sumitomo Pharma

- Dexcel Pharma

- Genentech

- Hitachi

- MJFF

- MedGenesis Therapeutix

- Mesoblast

- Neuropore Therapies

- Pfizer

- Prothena

- Sellas Life Sciences

- TechnoPhage

- UbiQ

- Ubiquigent

For more information visit

http://www.researchandmarkets.com/research/f9lg6m/parkinsons

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com